In type 2 diabetic mice, treatment with SGLT2 inhibitors decreased plasma glucose, albuminuria, mesangial expansion and glomerular hypertrophy, and inhibited inflammation and oxidative stress [21,22,23,24]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.